Stuffy in here, Part II

Sarah Lacy

More and more chatter about biotech IPOs this week, and a few more data points. In my reporting last week for this blog and this story, industry watchers (particularly bankers and VCs) pooh-poohed concerns about last week's biotech issues having to slash their prices in half to get out. It's merely a sign that investors want a cheap deal, not that they aren't interested in new issues, they said. What will the real red flag be? Companies postponing.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.